Related Experiment Video

Updated: May 13, 2026

Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging
09:20

Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging

Published on: October 27, 2023

A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer

Derek V Chan1, Rahul Sharma, Chiao-Ying A Ju

  • 1Department of Pathology, Boston University School of Medicine, Boston University, Boston, MA 02118, USA.

Journal of Biomedical Science
|March 19, 2013
PubMed
Abstract

Insights

Novel targeted cancer therapies using engineered cytotoxic agents show promise. Single chain antibodies fused to FasL demonstrated potent tumor cell killing and successful tumor eradication in mice.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Targeted cancer therapy aims to selectively eliminate tumor cells.
  • Previous attempts at targeted therapy have yielded limited success.
  • Novel cytotoxic agents combining antibody specificity with potent killing domains are under development.

Purpose of the Study:

  • To develop and evaluate novel targeted cytotoxic agents for cancer therapy.
  • To assess the efficacy of engineered FasL-based agents against specific tumor antigens.
  • To determine the in vivo therapeutic potential of these novel agents.

Main Methods:

  • Conjugation of the extracellular cytotoxicity domain of CD178 (FasL) to single chain antibodies (scFv).
  • Antibody specificity directed against human tumor antigens TAG-72 (cc49scFv) and TAL6 (L6scFv).
  • In vitro cytotoxicity assays and in vivo tumor models in SCID mice.

Main Results:

  • cc49scFv-FasLext exhibited a 30,000-fold increase in cytotoxicity against TAG-72+ Jurkat-Ras cells compared to soluble FasL.
  • L6scFv-FasLext showed a 500-fold increase in cytotoxicity against TAL6+ HeLa cells.
  • cc49scFv-FasLext demonstrated high specificity and efficacy, leading to the cure of established Jurkat-Ras tumors in mice.

Conclusions:

  • Engineered scFv-FasLext agents possess strong cytotoxicity against sensitive human tumor targets.
  • These novel agents hold potential as effective chemotherapeutic drugs.
  • Targeted delivery of cytotoxic domains via scFv offers a promising strategy for cancer treatment.

More Related Videos

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites14:27

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites

Published on: November 14, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...